FDA clears Michelson's VivoSight scanner
This article was originally published in Clinica
Executive Summary
Michelson Diagnostics' VivoSight optical coherence tomography (OCT) scanner has received 510(k) clearance from the US FDA. The device uses the firm's patented multi-beam OCT technology to provide real-time, sub-surface images of tissue at “far higher” resolution than other imaging methods, including ultrasound, CT and MRI. The handheld probe can generate two- or three-dimensional images of the epidermis, dermis and sub-surface blood vessels. Orpington, UK-based Michelson CE marked the scanner for sale in Europe in October 2009. In November, the company received a £25,000 grant from the UK government’s Technology Strategy Board to help develop miniaturised probes for use with the scanner for cancer diagnosis (www.clinica.co.uk, November 26 2009).